In 2013, EuroEyes successfully expanded to China – the first German clinic group. Today EuroEyes employs around 200 people at a total of 26 locations in Germany, Denmark and China and are still on a growth path.
Welcome to EuroEyes
OUR VISION IS CLEAR
Our role is to bring German ophthalmology excellence to our customers to permanently rid their need to wear glasses ever again. As our motto says it, “Nie wieder Brille! ”, meaning “no more glasses!”.
Our role as a vision correction services provider has evolved over the decades, influenced by changing demographics, economic prospects and technological development. The increasing wealth in Europe and the PRC and the ageing of these populations as well as the increase of myopia in younger generations have led us to define our future strategy.
Central to this is the increasing awareness of a variety of forms of refractive laser surgery as a mainstream alternative to glasses and contact lenses. We have had the vision to identify our key customer group as those between 18 and 45 years of age, likely to be seeking treatment for myopia or high myopia, and those over the age of 45, likely to be developing signs of presbyopia.
Hence, we have been focusing our services to tackle the refractive errors of these two customer groups. This is underpinned by our 25 years of experience and commitment in providing optimal solutions to all refractive surgery needs and to broaden the treatment scope of refractive surgery treatment options.
Being capable of offering a wide range of vision correction services, we aim to become a one-stop destination for customers in Germany, Denmark and the PRC (and also medical tourists from other countries) of all age groups from 18 years of age and beyond, to treat any refractive errors they may experience.
EXPANSION TO UK
EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1846), a leading global vision correction service provider, is pleased to announce that EuroEyes UK, a wholly-owned subsidiary of the Company, has entered into a Share Purchase Agreement (“Share Purchase Agreement”) to acquire the entire issued shares in London Vision Clinic Partners Limited (“LoVC”) with the legal and beneficial owners of LoVC (“Sellers”), for a maximum consideration of approximately £30,875,000 (“Consideration”). The Consideration will be satisfied by (a) the Completion Cash Consideration; (b) the Completion Consideration Shares; (c) the Contingent Cash Consideration and (d) the Earn-out Consideration Shares, and subject to the Consideration Adjustment.
EXPANSION TO ASIA
On October 15 2019, EuroEyes successfully listed the shares on the main board of The Stock Exchange of Hong Kong Limited.
“There is a huge need for vision correction in China. According to a market analysis, almost 90 percent of young people are short-sighted . We expect the Chinese short-sighted population to increase to 655 million people in 2023. Also presbyopia is corrected with trifocal lenses , which plays a major role, “said Dr. Jørgensen, the Chairman and CEO of EuroEyes.
EuroEyes has established itself in China as a high-end provider of surgical vision correction. Our unique selling points include the excellent reputation of German ophthalmology, the large number of operations performed, the early use of modern technologies, the quality and comfort of services, customer satisfaction and the excellent location of the clinics in the major cities.
REASONS FOR INVESTING IN THE EUROEYES GROUP
NEWS FOR INVESTORS
We make it clear that there is no public offer of shares in Germany or Denmark or within another country of the European Currency Area (“EEA”) or outside of Hong Kong.